You are here
-
Tumor necrosis factor/TNF beta/Lymphotoxin/LT alpha [9B9]
Description Lymphotoxin alpha or tumor necrosis beta, a member of the tumor necrosis factor family, is a cytokine produced by lymphocytes. LTA is highly inducible, secreted, and exists as homotrimeric molecule. LTA forms heterotrimers with lymphotoxin-beta which anchors lymphotoxin-alpha to the cell surface. LTA mediates a large variety of inflammatory, immunostimulatory, and antiviral responses. LTA is also involved in the formation of secondary lymphoid organs during development and plays a role in apoptosis. (Shipping Cost: €200.00) Host Mouse Application Immunocytochemistry (ICC),Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human -
Tyrosinase [T311 + OCA1/812]
Description Tyrosinase is a key enzyme involved in the initial stages of melanin biosynthesis. Tyrosinase catalyzes the hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA). Oxidation reactions of DOPA to L-Dopaquinone and 5,6-dihydroxyindole (DHI) to indole-quinone occur spontaneously at physiological pH. Tyrosinase is expressed in melanin-producing cells such as melanocytes, which are primarily localized in the skin, hair bulbs and eyes. Low levels of tyrosinase mRNA was also detected in the human substantia nigra, but immunohistochemically unreactive. Since melanomas arise from melanocytes, there is evidence that tyrosinase is expressed in malignant melanomas. Studies have shown that tyrosinase is a sensitive and reliable marker to assess melanocytic lesions in paraffin-embedded tissue (Shipping Cost: €200.00) Host Mouse Application Flow cytometry (FC), Immunofluorescence (IF), Immunohistochemistry (IHC) Reactivity Human -
Uroplakin II [EPR18799]
Description Uroplakin II is a 15 kDa protein component of urothelial plaques. Studies have shown Uroplakin II mRNA was highly specific and was expressed in both bladder cancer tissues and peripheral blood of patients with primary and metastatic urothelial carcinoma of the bladder. Uroplakin II is a highly specific and may be useful in identifying tumors of urothelial origin. (Shipping Cost: €200.00) Host Rabbit Application Immunohistochemistry (IHC) Reactivity Human -
Uroplakin II [EPR18799]
Description Uroplakin II is a 15 kDa protein component of urothelial plaques. Studies have shown Uroplakin II mRNA was highly specific and was expressed in both bladder cancer tissues and peripheral blood of patients with primary and metastatic urothelial carcinoma of the bladder. Uroplakin II is a highly specific and may be useful in identifying tumors of urothelial origin. (Shipping Cost: €200.00) Host Rabbit Application Immunohistochemistry (IHC) Reactivity Human -
Uroplakin III [EPR14420]
Description Uroplakins (UPs) are a family of transmembrane proteins (UPs Ia, Ib, II and III) that are specific differentiation products of urothelial cells. In non-neoplastic mammalian urothelium, UPs are expressed in the luminal surface plasmalemma of superficial (umbrella) cells, forming complexes of 16 nm crystalline particles. Moll et al. reported that UPIII was detectable immunohistochemically in 29 of 55 primary (53%) and 23 of 35 metastatic (66%) urothelial carcinomas, whereas many non- urothelial carcinomas were UPIII-negative. The authors concluded that anti-UPIII should be a valuable marker, especially for the specific identification of urothelial carcinomas in patients with metastases of unknown primary site. Subsequently, Olsburgh et al. studied UP gene expression in normal urothelium and bladder cancer specimens, and found that expression was absent after malignant transformation. Ohtsuka et al. concluded in their studies that UPIII expression was strongly associated with lower tumor Host Rabbit Application Flow cytometry (FC), Immunohistochemistry (IHC) Reactivity Human -
Uroplakin III [EPR14420]
Description Uroplakins (UPs) are a family of transmembrane proteins (UPs Ia, Ib, II and III) that are specific differentiation products of urothelial cells. In non-neoplastic mammalian urothelium, UPs are expressed in the luminal surface plasmalemma of superficial (umbrella) cells, forming complexes of 16 nm crystalline particles. Moll et al. reported that UPIII was detectable immunohistochemically in 29 of 55 primary (53%) and 23 of 35 metastatic (66%) urothelial carcinomas, whereas many non- urothelial carcinomas were UPIII-negative. The authors concluded that anti-UPIII should be a valuable marker, especially for the specific identification of urothelial carcinomas in patients with metastases of unknown primary site. Subsequently, Olsburgh et al. studied UP gene expression in normal urothelium and bladder cancer specimens, and found that expression was absent after malignant transformation. Ohtsuka et al. concluded in their studies that UPIII expression was strongly associated with lower tumor Host Rabbit Application Flow cytometry (FC), Immunohistochemistry (IHC) Reactivity Human -
USP6NL/RNTRE Polyclonal
Description Acts as a GTPase-activating protein for RAB5A and RAB43. Involved in receptor trafficking. In complex with EPS8 inhibits internalization of EGFR. Involved in retrograde transport from the endocytic pathway to the Golgi apparatus. Involved in the transport of Shiga toxin from early and recycling endosomes to the trans-Golgi network. Required for structural integrity of the Golgi complex. (Shipping Cost: €200.00) Host Rabbit Application ELISA, Immunohistochemistry (IHC) Reactivity Human -
VEGF/VEGFA [VG1]
Description VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines in vitro and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF. This clone recognizes proteins of 19-22 kDa (reducing) and 38-44 kDa (non-reducing), identified as various isoforms of VEGF or Vascular Permeability Factor (VEGF/VPF). (Shipping Cost: €200.00) Host Mouse Application ELISA, Immunohistochemistry (IHC) Reactivity Human -
VEGF/VEGFA [VG1]
Description VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines in vitro and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF. This clone recognizes proteins of 19-22 kDa (reducing) and 38-44 kDa (non-reducing), identified as various isoforms of VEGF or Vascular Permeability Factor (VEGF/VPF). (Shipping Cost: €200.00) Host Mouse Application ELISA, Immunohistochemistry (IHC) Reactivity Human -
VEGFC (Flt4L) Polyclonal
Description Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors. (Shipping Cost: €200.00) Host Rabbit Application Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse, Rat